Lumos secures US$5m FebriDx milestone payment as US rollout gains traction

0
134
Lumos secures US$5m FebriDx milestone payment as US rollout gains traction Proactive uses images sourced from Shutterstock

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a US$5 million milestone pre-payment from its US distribution partner Phase Scientific, with its FebriDx® point-of-care test now moving into broader commercial rollout across the United States.

The payment follows the recent US Food and Drug Administration 510(k) clearance and CLIA waiver for FebriDx®, which satisfies a major milestone under the companies’ distribution agreement.

Importantly, the funds are a pre-payment for future product orders rather than immediate revenue, and will be recognised progressively as purchase orders are fulfilled and units shipped.

The latest instalment brings total pre-payments received from Phase Scientific to US$7.5 million, building on an…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here